NBIX
NASDAQ · Biotechnology
Neurocrine Biosciences Inc
$152.25
+2.66 (+1.78%)
Performance
1D
—
1W
—
1M
—
3M
+10.61%
6M
+3.68%
1Y
+26.42%
YTD
+8.29%
Open$150.00
Previous Close$149.59
Day High$154.74
Day Low$149.54
52W High$160.18
52W Low$115.66
Volume—
Avg Volume1.38M
Market Cap15.33B
P/E Ratio32.02
EPS$4.66
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$139.44
Above
SMA 200
$135.94
Above
RSI (14)
38.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
35 analysts
Price Target
-16.6% upside
Current
$152.25
$152.25
Target
$126.93
$126.93
$104.30
$126.93 avg
$177.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.81B | 2.26B | 5.53B |
| Net Income | 470.05M | 340.29M | 497.45M |
| Profit Margin | 16.7% | 15.9% | 9.0% |
| EBITDA | 633.58M | 484.15M | 909.27M |
| Free Cash Flow | — | — | 422.12M |
| Rev Growth | +24.3% | +24.3% | -8.7% |
| Debt/Equity | — | — | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |